The review says that a type of cell death called ferroptosis makes brain damage worse after a bleed in the brain, and that some drugs, including the diabetes drug semaglutide, might block this process and protect neurons. However, the evidence is still early and comes from lab studies, not human trials, so it isn’t ready to be turned into a DIY health protocol.

Aneurysmal Subarachnoid Hemorrhage (SAH) is a devastating cerebrovascular event with high morbidity and mortality rates, and early brain injury following SAH (EBI-SAH) within 72 h leads to a poor prognosis. Despite advances in our understanding of the pathogenesis of EBI-SAH, effective therapeutic strategies remain elusive. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation and failure of antioxidant defense, has emerged as a key contributor to neuronal damage in EBI-SAH. This review aims to synthesize knowledge regarding the core molecular mechanisms of ferroptosis, focusing on its role in EBI-SAH initiation and regulation, and comprehensively evaluate diverse pharmacological agents that inhibit ferroptosis to mitigate EBISAH. Natural products (e.g., dihydroquercetin and ginsenoside Rd), synthetic ferroptosis inhibitors (e.g., ferrostatin-1 and deferoxamine), nanomedicines, and small molecules (e.g., melatonin and semaglutide) exert neuroprotective effects by targeting ferroptosis pathways, including the glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis, Nrf2 signaling, iron chelation, and lipid peroxidation suppression. The findings of this study underscore the therapeutic potential of ferroptosis inhibition as a novel strategy to ameliorate EBI-SAH and provide a foundation for future translational research.